Quince Therapeutics Announced Online Publication Of Data In Lancet Neurology From Its Phase 3 ATTeST Trial Of Its Lead Asset, Erydex (Dexamethasone Sodium Phosphate Encapsulated In Autologous Erythrocytes), For Ataxia-Telangiectasia
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics announced the online publication of data from its Phase 3 ATTeST trial of Erydex in Lancet Neurology. The study showed a favorable safety profile and positive effects in a subset of patients with Ataxia-Telangiectasia. Quince has also initiated a pivotal Phase 3 NEAT study under a U.S. FDA Special Protocol Assessment agreement.
August 15, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quince Therapeutics published positive Phase 3 trial data for Erydex in Lancet Neurology, showing safety and efficacy in young A-T patients. The company has also initiated a pivotal Phase 3 NEAT study under a U.S. FDA Special Protocol Assessment agreement.
The publication of positive Phase 3 trial data in a reputable journal like Lancet Neurology is a significant milestone for Quince Therapeutics. The favorable safety profile and efficacy in a critical patient subset can boost investor confidence. Additionally, the initiation of the pivotal Phase 3 NEAT study under an FDA agreement further strengthens the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100